BioSenic S.A. (EBR:BIOS)

Belgium · Delayed Price · Currency is EUR

0.0020

0.00 (0.00%)

At close: Oct 9, 2026

Market Cap	1.31M -16.7%
Revenue (ttm)	-2.39M -69.6%
Net Income	-4.00M
EPS	-0.01
Shares Out	652.86M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	n/a
Previous Close	0.0020
Day's Range	n/a
52-Week Range	0.0018 - 0.0028
Beta	-1.58
Analysts	n/a
Price Target	n/a
Est. Earnings	Dec 24, 2026

About BioSenic

BioSenic S.A., a biotechnology company, develops cell therapy products and treatments for autoimmune and inflammatory diseases in Belgium and France. The company offers arsenic trioxide (ATO) and oral arsenic trioxide (OATO) platforms. It also provides medicinal products, including ArsciMed, an intravenous drug to treat autoimmune diseases. In addition, the company develops 4P004v which is in Phase I clinical trial for veterinary use. BioSenic S.A. is headquartered in Saintes, Belgium. [Read more]

Industry Biotechnology

Sector Healthcare

CEO Jean-Luc Vandebroek

Employees 7

Stock Exchange Euronext Brussels

Ticker Symbol BIOS

Full Company Profile

Financial Performance

In 2024, BioSenic's revenue was 102,000, a decrease of -69.64% compared to the previous year's 336,000. Losses were -4.77 million, -83.43% less than in 2023.

Financial Statements